Doubling down on modest data

A look at some recent phase 2 data in the KRAS niche in the context of the broader landscape

January 27, 2022

Important changes to watch out for in the GI cancer landscape

Preview of what to watch out for at ASCO GI22

January 18, 2022

New developments in GI cancers from ASCO GI 2020

A report card on important trial updates across gastric, pancreatic, liver, and colorectal cancers at ASCO GI 2020.

January 27, 2020

The Yin and Yang of biomarkers in cancer research

Some examples of potentially useful biomarker inclusion in early oncology trials

January 22, 2019

Insights from the ASCO GI19 conference

What to watch out for at the ASCO GI19 conference in San Francisco

January 17, 2019

Immune Landscape of Pancreatic Cancer

A look at where we are in pancreatic cancer and how the landscape has evolved of late...

January 25, 2018

ASCO GI18 Preview

A look at 8 key abstracts being presented at #GI18 in San Francisco this week.

January 17, 2018

ASCO GI17 Gems from the Poster Hall

A look at gems from the #GI17 poster halls or molecules destined for Dog Drug Heaven?

January 27, 2017

Is 2017 the Year of the Cancer Vaccine?

A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.

February 21, 2017

New developments in advanced colorectal cancer

A couple of trials at ASCO #GI17 look promising in terms of trial design with encouraging implications for the future in metastatic colorectal cancer.

January 26, 2017

Will nivolumab make an impact in gastric cancer?

Will gastric cancer be one of the next indications for nivolumab?

January 25, 2017

Update on Targeted therapies and Immunotherapies in Gastric Cancer

Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?

January 27, 2016

Will pembrolizumab extend its activity in GI cancers?

Will checkpoint blockade be effective in multiple GI cancers and if so, why?

January 25, 2016

Overcoming acquired resistance to EGFR therapies in colorectal cancer

Which new combinations could improve outcomes for colon cancer patients receiving EGFR therapies by overcoming acquired resistance?

February 19, 2015

Molecular Characterisation of Colorectal Cancer

We've seen very little real progress in colorectal cancer beyond incremental improvements since Erbitux and Avastin were approved a decade ago. Are we on the threshold of a new paradigm shift?

February 17, 2015

Overcoming acquired resistance to BRAF in colorectal cancer

Patients with BRAF driven colon cancer don't do as well as those with melanoma: how can we overcome acquired resistance to RAF treatment?

February 13, 2015

Precision medicine in advanced colorectal cancer

If we truly want to see a more precision medicine approach evolve then we have to first find the oncogenic drivers. At ASCO GI one study in particular caught my eye and attention, but you won’t find it written up in the medical lay press and it’s not that obvious unless you know what you’re looking for.

January 20, 2015

ASCO GI Keynote: The future of Immunotherapy is Combinations

“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.

January 21, 2014

ASCO GI 2014 Preview: Pancreatic and Gastric Cancer

Preview of some of the key data being presented at ASCO GI in San Francisco this month.

January 3, 2014